Cambridge Temperature Concepts Announces New CEO Claire Hooper
News Dec 23, 2013
Cambridge Temperature Concepts (CTC) has announced the appointment of Dr. Claire Hooper as Chief Executive Officer and a member of the Board of Directors, effective 9 December 2013.
Dr. Hooper brings global technology experience to this innovative telemedicine company and has a strong track record in developing and commercializing cutting-edge technologies internationally through partnership and M&A deals.
She brings more than 20 years of relevant industry experience, having previously served as technology director in PerkinElmer and Cambridge Imaging.
Sherry Coutu CBE, CTC’s Co-Chair, investor and serial entrepreneur, welcomes Dr. Hooper’s experience and leadership. She says: “In her new role as chief executive Claire will be responsible for delivering against an ambitious 2014 plan which focuses on rolling out our DuoFertility products in the US and developing the CTC platform within other related healthcare areas. Her results-oriented approach and ability to think strategically will provide the leadership and experience to help us grow.”
DuoFertility accurately predicts ovulation, optimizing a woman’s chances of successful conception. This proven application of telemedicine, based on the latest advances in wireless sensing technology, has created a platform that can be used to deliver other types of remote monitoring.
With Dr Hooper’s appointment, CTC Founder Dr. Shamus Husheer will take the role of Chief Technology Officer. Dr. Husheer says, “We are delighted that Dr. Hooper has agreed to take the commercial lead. She has the experience to drive the business forward and exploit effectively the significant market opportunities that lie ahead.”
Dr. Hooper says that telemedicine is a major opportunity: “CTC founders have put the company at the forefront of this expanding market. I am excited at the prospect of building on this and fully exploiting the opportunities in telemedicine, big data and digital health.”
Life sciences entrepreneur and investor, Dr. Andy Richards, Co-Chair at CTC, says that prior to appointment Claire had been an adviser and played an impressive role in leading and working with the CTC team.
“Claire has considerable experience of scaling healthtech operations. One of her objectives will be to commercialize the CTC platform and expand its use into other important medical areas where m-Health can make a real difference to patients.”
Dr. Hooper has a PhD in biochemistry and also serves as a non-executive director on the board of Abcodia Limited.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018